Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Self-citationCharacterization of a human B lymphocyte-specific antigen.
Stashenko, P., Nadler, L. M., Hardy, R., & Schlossman, S. F. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.4.1678 · Cited by 1,076
Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody
Miller, R. A., Maloney, D. G., Warnke, R., & Levy, R. (1982) · New England Journal of Medicine · doi:10.1056/nejm198203043060906 · Cited by 985
Maloney, D. G., Grillo-López, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3266 · Cited by 636
Self-citationMonoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
Press, O., Appelbaum, F., Ledbetter, J., Martin, P., Zarling, J., Kidd, P., & Thomas, E. (1987) · Blood · doi:10.1182/blood.v69.2.584.584 · Cited by 361
Ngan, B., Chen-Levy, Z., Weiss, L. M., Warnke, R. A., & Cleary, M. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806233182502 · Cited by 304
Einfeld, D. A., Brown, J. P., Valentine, M. A., Clark, E. A., & Ledbetter, J. A. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02867.x · Cited by 278
The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.
Tedder, T. F., Boyd, A. W., Freedman, A. S., Nadler, L. M., & Schlossman, S. F. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.2.973 · Cited by 226
Golay, J. T., Clark, E. A., & Beverley, P. C. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.6.3795 · Cited by 175
Cited by
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Davis, T. A., Grillo-López, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., & Levy, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3135 · Cited by 687
Self-citationImmunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Salles, G., Barrett, M., Foà, R., Maurer, J., O’Brien, S., Valente, N., Wenger, M., & Maloney, D. G. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0612-x · Cited by 620
Rituximab: A Review of its Use in Non-Hodgkin??s Lymphoma and Chronic Lymphocytic Leukaemia
Plosker, G. L., & Figgitt, D. P. (2003) · Drugs · doi:10.2165/00003495-200363080-00005 · Cited by 471
Tolerability and safety of rituximab (MabThera®)
Kimby, E. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.05.007 · Cited by 470
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 438
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
Conconi, A. (2003) · Blood · doi:10.1182/blood-2002-11-3496 · Cited by 402
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Huhn, D. (2001) · Blood · doi:10.1182/blood.v98.5.1326 · Cited by 347
Beers, S. A., French, R. R., Chan, H. T. C., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S., Dixon, S. V., Kim, H., Cox, K. L., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263533 · Cited by 335
Improvement of Sjögren's syndrome after two infusions of rituximab (anti‐CD20)
Devauchelle‐Pensec, V., Pennec, Y., Morvan, J., Pers, J., Daridon, C., Jousse‐Joulin, S., Roudaut, A., Jamin, C., Renaudineau, Y., Roué, I. Q., et al. (2007) · Arthritis Care & Research · doi:10.1002/art.22536 · Cited by 315
New insights into the pathogenesis and nonsurgical management of Graves orbitopathy
Taylor, P. N., Zhang, L., Lee, R. W. J., Muller, I., Ezra, D. G., Dayan, C. M., Kahaly, G. J., & Ludgate, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0305-4 · Cited by 315
Dalakas, M. C., Rakocevic, G., Salajegheh, M., Dambrosia, J. M., Hahn, A. F., Raju, R., & McElroy, B. (2009) · Annals of Neurology · doi:10.1002/ana.21577 · Cited by 312
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fervenza, F. C., Abraham, R. S., Erickson, S. B., Irazabal, M. V., Eirin, A., Specks, U., Nachman, P. H., Bergstralh, E. J., Leung, N., Cosio, F. G., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05080610 · Cited by 299
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
Boye, J., Elter, T., & Engert, A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg175 · Cited by 294
Rituximab treatment of idiopathic membranous nephropathy
Fervenza, F. C., Cosio, F. G., Erickson, S. B., Specks, U., Herzenberg, A. M., Dillon, J. J., Leung, N., Cohen, I. M., Wochos, D. N., Bergstralh, E., et al. (2008) · Kidney International · doi:10.1038/sj.ki.5002628 · Cited by 265
Treatment of Waldenström’s Macroglobulinemia With Rituximab
Dimopoulos, M. A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N. A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.039 · Cited by 253
Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma
Leonard, J. P., Coleman, M., Ketas, J. C., Chadburn, A., Ely, S., Furman, R. R., Wegener, W. A., Hansen, H. J., Ziccardi, H., Eschenberg, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.082 · Cited by 253
Metadata
- Authors
- Piro, L. D., White, C. A., Grillo-López, A. J., Janakiraman, N., Saven, A., Beck, T. M., Varns, C., Shuey, S., Czuczman, M., Lynch, J. W., Kolit, J. E., & Jain, V.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 1999-06
- Volume
- 10
- Issue
- 6
- Pages
- 655-661
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2099314298
- Cited by
- 368
- References
- 11
- FWCI
- 11.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.